1. |
|
|
2. |
- Cardenas, EI, et al.
(författare)
-
IL-26 in asthma and COPD
- 2022
-
Ingår i: Expert review of respiratory medicine. - 1747-6356. ; , s. 1-9
-
Tidskriftsartikel (refereegranskat)
|
|
3. |
- Cardenas, EI, et al.
(författare)
-
IL-26 in asthma and COPD
- 2022
-
Ingår i: Expert review of respiratory medicine. - : Informa UK Limited. - 1747-6356 .- 1747-6348. ; 16:3, s. 293-301
-
Tidskriftsartikel (refereegranskat)
|
|
4. |
|
|
5. |
- Cardenas, EI, et al.
(författare)
-
Increased IL-26 associates with markers of hyperinflammation and tissue damage in patients with acute COVID-19
- 2022
-
Ingår i: Frontiers in immunology. - : Frontiers Media SA. - 1664-3224. ; 13, s. 1016991-
-
Tidskriftsartikel (refereegranskat)abstract
- Interleukin-26 (IL-26) is released by several immune and structural cells following stimulation of toll-like receptors (TLRs), whereupon it can directly inhibit viral replication and enhance neutrophil chemotaxis. Given these unique properties, IL-26 has emerged as an intriguing mediator of host defense in the lungs. However, the role of IL-26 in COVID-19 has not been thoroughly investigated. Here, we characterized the involvement of IL-26 in the hyperinflammation and tissue damage that occurs in patients with acute COVID-19. We found that IL-26 is markedly increased in blood samples from these patients, and that the concentration of IL-26 correlates with those of the neutrophil-mobilizing cytokines IL-8 and TNFα, respectively. Moreover, the increase in blood IL-26 correlates with enhanced surface expression of the “don’t eat me” signal CD47 on blood neutrophils isolated from patients with acute COVID-19. Finally, we found that the blood concentration of IL-26 correlates with that of increased lactate dehydrogenase, an established marker of tissue damage, and decreased mean corpuscular hemoglobin (MCH), a previously verified hematological aberration in COVID-19, both of which are associated with severe disease. Thus, our findings indicate that increased systemic IL-26 associates with markers of hyperinflammation and tissue damage in patients with acute COVID-19, thereby forwarding the kinocidin IL-26 as a potential target for diagnosis, monitoring, and therapy in this deadly disease.
|
|
6. |
|
|
7. |
|
|
8. |
|
|